Actuate Therapeutics, Inc.

Stage 4 · Declining · week 42

As of Oct 22, 2026, Actuate Therapeutics is in Stage 4, the downtrend phase, now in week 42 (since Dec 29, 2025). It closed at $0.52, 93.2% below its 52-week high and below its 200-day average, which is falling.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. More about the company

$0.52

-6.66% today

$12.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ACTU early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-08-13 → 2026-10-22

S? 41w

S4 43w

2024-08-132026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S2 5w → S3 2w → S4 7w → S1 7w → S4 7w → S1 1w → S4 43w current

Total tracked: 114 weeks across 8 stage runs.

ACTU among Biotechnology521st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…521	ACTUActuate Therapeutics, Inc.	Stage 4 · wk 42	6	−29.5%

vs 52W High

-93.2%

$0.43 lo$7.63 hi

93.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 42

1w13w26w

Week 42, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-77.8%

200 DMA: $2.32 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.84x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.5%

-56.3%

-79.6%

YTD

-91.4%

-93.0%

Scan Membership

Breakout Watch

Latest: 2025-05-30

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 42 · Vol 0.84x

2026-10-21S4

Wk 41 · Vol 0.53x

2026-10-20S4

Wk 41 · Vol 0.42x

2026-10-19S4

Wk 41 · Vol 1.87x

2026-10-16S4

Wk 41 · Vol 2.47x

2026-10-15S4

Wk 41 · Vol 1.28x

2026-10-14S4

Wk 40 · Vol 1.20x

2026-10-13S4

Wk 40 · Vol 2.76x

2026-10-12S4

Wk 40 · Vol 0.82x

2026-10-09S4

Wk 40 · Vol 0.85x

2026-10-08S4

Wk 40 · Vol 0.95x

2026-10-07S4

Wk 39 · Vol 1.91x

Moving averages & range

50 DMA

$0.98

200 DMA

$2.32

52W High

$7.63

52W Low

$0.43

5D Low

$0.52

Resistance levels (recent highs)

20d High

$0.89

60d High

$1.78

120d High

$3.34

250d High

$7.63

Next resistance

+72.3%

to 20d High

Dividend Yield

0.00%

P/B 12.6

Actuate Therapeutics: quick answers

What stage is Actuate Therapeutics in?

As of Oct 22, 2026, Actuate Therapeutics (ACTU) is in Stage 4, the downtrend phase. It entered Stage 4 on Dec 29, 2025 and is in week 42. What the four stages mean

Is Actuate Therapeutics in an uptrend?

No. Actuate Therapeutics is in a Stage 4 downtrend. It trades 77.8% below its 200-day average, which is falling.

How far is Actuate Therapeutics from its 52-week high?

Actuate Therapeutics closed at $0.52 on Oct 22, 2026, 93.2% below its 52-week high of $7.63. Its 52-week low is $0.43.

How has Actuate Therapeutics performed over the past year?

As of Oct 22, 2026, Actuate Therapeutics is down 93.0% over the past year and down 91.4% so far in 2026.

Which sector and industry is Actuate Therapeutics in?

Actuate Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.